Ionis Pharmaceuticals (LTS:0JDI) Piotroski F-Score: 2 (As of Jun. 28, 2026) — 60% Below Median


LTS:0JDI Ionis Pharmaceuticals Inc LTS:0JDI
66 GF Score
Price $80.36
GF Value $53.57
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Piotroski F-Score?

Ionis Pharmaceuticals LTS:0JDI +2.08% 66 Piotroski F-Score is 2 as of Jun. 28, 2026, which is 60% below its 10-year median of 5.00. GuruFocus rates LTS:0JDI with a GF Score™ of 66/100 and a GF Value™ of $53.57 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,342 Biotechnology companies, Ionis Pharmaceuticals ranks worse than 73.1% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ionis Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Ionis Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

LTS:0JDI' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 7
Current: 2

During the past 13 years, the highest Piotroski F-Score of Ionis Pharmaceuticals was 7. The lowest was 1. And the median was 5.

Ionis Pharmaceuticals  (LTS:0JDI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ionis Pharmaceuticals Piotroski F-Score Related Terms


Ionis Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Piotroski F-Score Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 0.00 4.00 2.00 3.00

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 5.00 5.00 3.00 2.00

LTS:0JDI vs EXEL, BBIO, AXSM: Piotroski F-Score Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Piotroski F-Score falls into.


LTS:0JDI
66GF Score
Ionis Pharmaceuticals Inc LTS:0JDI
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 123.551 + -128.606 + -229.394 + -92.528 = $-327 Mil.
Cash Flow from Operations was 151.338 + -131.437 + -137.709 + -792.819 = $-911 Mil.
Revenue was 452.049 + 156.719 + 203.33 + 246.091 = $1,058 Mil.
Gross Profit was 447.898 + 154.381 + 195.373 + 243.091 = $1,041 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2812.948 + 2985.133 + 3033.091 + 3523.836 + 3449.969) / 5 = $3160.9954 Mil.
Total Assets at the begining of this year (Mar25) was $2,813 Mil.
Long-Term Debt & Capital Lease Obligation was $1,608 Mil.
Total Current Assets was $2,937 Mil.
Total Current Liabilities was $717 Mil.
Net Income was -66.265 + -140.48 + -104.349 + -146.938 = $-458 Mil.

Revenue was 225.25 + 133.814 + 226.576 + 131.612 = $717 Mil.
Gross Profit was 221.086 + 132.743 + 222.746 + 130.112 = $707 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2763.928 + 2691.128 + 3081.099 + 3003.675 + 2812.948) / 5 = $2870.5556 Mil.
Total Assets at the begining of last year (Mar24) was $2,764 Mil.
Long-Term Debt & Capital Lease Obligation was $1,410 Mil.
Total Current Assets was $2,419 Mil.
Total Current Liabilities was $250 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ionis Pharmaceuticals's current Net Income (TTM) was -327. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ionis Pharmaceuticals's current Cash Flow from Operations (TTM) was -911. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-326.977/2812.948
=-0.11623997

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-458.032/2763.928
=-0.16571778

Ionis Pharmaceuticals's return on assets of this year was -0.11623997. Ionis Pharmaceuticals's return on assets of last year was -0.16571778. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ionis Pharmaceuticals's current Net Income (TTM) was -327. Ionis Pharmaceuticals's current Cash Flow from Operations (TTM) was -911. ==> -911 <= -327 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1608.454/3160.9954
=0.50884414

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1410.11/2870.5556
=0.49123243

Ionis Pharmaceuticals's gearing of this year was 0.50884414. Ionis Pharmaceuticals's gearing of last year was 0.49123243. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2936.945/716.591
=4.09849552

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2418.932/250.293
=9.66440132

Ionis Pharmaceuticals's current ratio of this year was 4.09849552. Ionis Pharmaceuticals's current ratio of last year was 9.66440132. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ionis Pharmaceuticals's number of shares in issue this year was 164.874. Ionis Pharmaceuticals's number of shares in issue last year was 158.735. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1040.743/1058.189
=0.98351334

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=706.687/717.252
=0.98527017

Ionis Pharmaceuticals's gross margin of this year was 0.98351334. Ionis Pharmaceuticals's gross margin of last year was 0.98527017. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1058.189/2812.948
=0.37618506

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=717.252/2763.928
=0.25950459

Ionis Pharmaceuticals's asset turnover of this year was 0.37618506. Ionis Pharmaceuticals's asset turnover of last year was 0.25950459. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ionis Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
Ionis Pharmaceuticals (LTS:0JDI) has a Piotroski F-Score of 2 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ionis Pharmaceuticals and its competitors. This is 60% below median its historical median of 5.00. Over the past decade, Ionis Pharmaceuticals' Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Ionis Pharmaceuticals ranks #981 out of 1342 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Ionis Pharmaceuticals' Piotroski F-Score too high?
Ionis Pharmaceuticals' current Piotroski F-Score of 2 is 60% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Ionis Pharmaceuticals' value of 2 is 33.3% below this industry median. Based on the distribution chart, Ionis Pharmaceuticals ranks #981 out of 1342 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Piotroski F-Score compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #981 out of 1342 companies for Piotroski F-Score. This places Ionis Pharmaceuticals in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Ionis Pharmaceuticals' value of 2 is 33.3% below this benchmark. Historically, Ionis Pharmaceuticals' own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Ionis Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ionis Pharmaceuticals's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current Piotroski F-Score is 2, which is 60% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.57, compared to a current price of $80.36 — trading 50% above its estimated fair value. The current Piotroski F-Score is 2, which is 60% below median its 10-year median of 5.00 and 33.3% below the Biotechnology industry median of 3.00. Ionis Pharmaceuticals' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Piotroski F-Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $80.36 is trading 50% above its estimated GF Value™ of $53.57. GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for LTS:0JDI:

  • Piotroski F-Score: 2 (60% below median its 10-year median of 5.00)
  • GF Value™: $53.57 vs. price of $80.36 (50% above fair value)
  • GF Score™: 66/100 with 8 warning signs
  • Industry Position: 33.3% below the Biotechnology median (#981 of 1342)

No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
66GF Score

Get the complete analysis for LTS:0JDI

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.36
Price
$53.57
GF Value